Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13474MR)

This product GTTS-WQ13474MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ERBB2&TNFRSF9 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001005862.3; NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 3604
UniProt ID P04626; Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13474MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3481MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ12556MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NV-01
GTTS-WQ13208MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ5718MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ10989MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ1615MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ9816MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ931MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-321
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW